BioSig Technologies, Inc. (BSGM) - Dilution Analysis

10-Q filing | 104.3M shares outstanding

8-K filing: Streamex Corp. completed a public offering of 11,666,667 shares of common stock at $3.00 per share, and the underwriters exercised their over-allotment option to purchase an additional 1,750,000 shares. ($40.25M proceeds)

8-K filing: Streamex Corp. acquired a 9.9% equity interest in Empress Royalty Corp. by issuing 2,443,750 shares of its common stock in exchange for 12,671,297 shares of Empress common stock. ($12.22M proceeds)

S-3/A filing: This prospectus relates to the offer and sale, from time to time, by the selling security holders identified in this prospectus of up to 27,883,241 shares of the common stock of Streamex Corp.

S-3 filing: This prospectus relates to the offer and sale, from time to time, by the selling security holders identified in this prospectus of up to 27,885,987 shares of the common stock of Streamex Corp.

10-Q filing | 39.5M shares outstanding

10-Q filing | 31.4M shares outstanding

8-K filing: BioSig Technologies, Inc. entered into a share purchase agreement with Streamex Exchange Corporation to acquire all of Streamex's shares, with ExchangeCo issuing 109,070,079 exchangeable shares, subject to stockholder approval and other conditions; a special voting preferred stock will be created.

10-Q filing | 27.3M shares outstanding

8-K filing: BioSig Technologies, Inc. issued 2,750,000 restricted shares of its common stock to certain service providers for business development services.

10-K filing | 24.3M shares outstanding

8-K filing: BioSig Technologies, Inc. sold an aggregate of 5,172,321 shares for an aggregate consideration of $4,847,497 from January 17, 2025 until March 5, 2025, through the Company's At the Market Offering Agreement with H.C. Wainwright & Co., LLC and a Securities Purchase Agreement with certain accredited investors. ($4.85M proceeds)

8-K filing: BioSig Technologies, Inc. sold 758,514 shares of common stock at $1.07974 per share and warrants to purchase up to 758,514 shares at an exercise price of $0.95474 per share for aggregate consideration of $818,997.91; also, from January 17, 2025 through March 5, 2025, the Company sold 4,413,807 shares at an average offering price of $0.912704 per share for aggregate gross proceeds of $4,028,498.73 through an At The Market Offering. ($5.67M proceeds)

8-K filing: BioSig Technologies, Inc. entered into an Equity Subscription Agreement with Lind Global Fund III, LP, allowing the Company to sell up to $5.0 million of its common stock, with 108,542 shares issued to the Investor as consideration for their commitment.

S-3/A filing: The company may offer and sell up to $75,000,000 of common stock and preferred stock from time to time.

10-Q filing | 16.2M shares outstanding

10-Q filing | 16.3M shares outstanding

S-1/A filing: This prospectus relates to the resale of up to 1,680,631 shares of common stock issuable upon the exercise of outstanding warrants issued on May 30, 2024.

S-1 filing: This prospectus relates to the resale by the selling stockholders of up to 1,680,631 shares of our common stock issuable upon the exercise of outstanding warrants issued on May 30, 2024.

8-K filing: BioSig Technologies, Inc. closed a registered direct offering and concurrent private placement on May 30, 2024, selling 1,570,683 shares of common stock at $1.91 per share and issuing warrants to purchase up to 1,570,683 shares, raising gross proceeds of approximately $3.0 million. ($3.0M proceeds)

10-Q filing | 12.5M shares outstanding

8-K filing: BioSig Technologies, Inc. sold 783,406 shares of common stock and warrants to purchase up to 391,703 shares to accredited investors at $1.4605 per share, for aggregate consideration of $1,144,164.46. ($1.14M proceeds)

10-K filing | 11.2M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 88,107,565 → 9,334,636

8-K filing: BioSig Technologies, Inc. sold 2,607,170 shares of common stock and warrants to purchase up to 1,303,585 shares to accredited and institutional investors at a purchase price of $0.3989 per share, with gross proceeds of $1,040,000.11. ($2.08M proceeds)

S-3/A filing: The filing is for a shelf registration allowing the company to offer and sell up to $75,000,000 of common stock and preferred stock.

S-3 filing: The filing is an S-3 shelf registration for the potential offering of up to $75,000,000 in common stock and preferred stock.

10-Q filing | 88.1M shares outstanding

8-K filing: BioSig Technologies, Inc. closed a registered direct offering on November 13, 2023, selling 6,996,922 shares of common stock, Series A warrants, and Series B warrants to an institutional investor at $0.3573 per share and associated warrants, resulting in net proceeds of approximately $2.2 million for working capital and general corporate purposes.

8-K filing: BioSig Technologies, Inc. sold 1,129,996 shares of common stock and warrants to purchase up to 564,998 shares to accredited investors at $0.52876 per share, with gross proceeds of $597,496.72, and issued a warrant to Laidlaw & Company (UK) Ltd. to purchase 84,750 shares at an exercise price of $0.46626 per share as partial compensation. ($0.6M proceeds)

8-K filing: BioSig Technologies, Inc. sold 1,458,770 shares of common stock and warrants to purchase up to 729,385 shares of common stock to accredited and institutional investors for aggregate consideration of $810,200.84, and issued a warrant to Laidlaw & Company (UK) Ltd. to purchase 40,511 shares of common stock as partial compensation for financial advisory services. ($0.81M proceeds)

8-K filing: BioSig Technologies, Inc. sold 990,954 shares of common stock and warrants to purchase up to 495,477 shares of common stock at a purchase price of $0.55502 per share, in exchange for aggregate consideration of $549,999.29. ($0.55M proceeds)

8-K filing: BioSig Technologies, Inc. entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. for an at the market offering of common stock and issued 950,000 shares of common stock to service providers.

10-Q filing | 74.9M shares outstanding

8-K filing: BioSig Technologies, Inc. sold 1,467,624 shares of common stock to an accredited investor at a price of $1.02206 per share, along with a warrant to purchase up to 733,812 shares at an exercise price of $0.95956 per share, for aggregate consideration of $1,499,999.79. ($1.5M proceeds)

8-K filing: BioSig AI, a subsidiary of BioSig Technologies, Inc., sold 495,000 shares of common stock at $1.00 per share for an aggregate purchase price of $495,000 in a private placement. ($0.5M proceeds)

8-K filing: BioSig AI, a subsidiary of BioSig Technologies, Inc., sold 1,710,000 shares of its common stock at $1.00 per share for gross proceeds of $1,710,000 in a private placement that closed on June 30, 2023. Additionally, BioSig AI issued a warrant to Laidlaw & Company (UK) Ltd. to purchase 90,000 shares of Common Stock at an exercise price of $1.00 per share. ($1.71M proceeds)

8-K filing: BioSig Technologies, Inc. sold 1,798,452 shares of common stock at $1.3905 per share and warrants to purchase up to 899,226 shares at an exercise price of $1.328 per share to institutional and accredited investors for $2,500,747.51, and issued a warrant to Laidlaw & Company (UK) Ltd. to purchase 62,698 shares of common stock at an exercise price of $1.328 per share. ($2.5M proceeds)

10-Q filing | 70.5M shares outstanding

8-K filing: BioSig Technologies, Inc. sold 792,454 shares of common stock and warrants to purchase up to 396,227 shares to accredited and institutional investors at $1.1925 per share, and issued a warrant to Laidlaw & Company (UK) Ltd. to purchase 7,862 shares at $1.13 per share. ($0.95M proceeds)

10-K filing | 66.9M shares outstanding

8-K filing: BioSig Technologies, Inc. sold 935,130 shares of common stock at $1.0885 per share and warrants to purchase up to 467,565 shares at an exercise price of $1.026 per share, for aggregate consideration of $1,017,889.00. ($1.02M proceeds)

8-K filing: BioSig Technologies, Inc. sold 1,550,540 shares of common stock and warrants to purchase up to 775,270 shares of common stock to institutional and accredited investors at a purchase price of $1.10928 per share, with warrants exercisable at $1.04678 per share, for aggregate consideration of $1,719,983.01. ($1.72M proceeds)

8-K filing: BioSig Technologies, Inc. sold 382,308 shares of common stock and warrants to purchase up to 191,154 shares of common stock to accredited investors for $409,994.75. ($0.41M proceeds)

8-K filing: BioSig Technologies, Inc. completed two unregistered sales of equity securities. The first sale involved the issuance of 1,591,750 shares of common stock and warrants to purchase up to 795,875 shares for $1,366,994.90. The second involved the issuance of 2,178,316 shares of common stock and warrants to purchase up to 1,089,158 shares for $1,254,884.28. ($2.62M proceeds)

8-K filing: The company sold 1,665,384 shares of Common Stock at a purchase price of $0.7806 per share and issued a warrant to purchase up to 832,692 shares of Common Stock at an exercise price of $0.7181 per share in exchange for consideration of $1,299,998.75. ($1.3M proceeds)

8-K filing: BioSig Technologies, Inc. sold 196,872 shares of common stock and warrants to purchase up to 98,436 shares to institutional and accredited investors at a purchase price of $0.8127 per share, in exchange for aggregate consideration of $159,997.87. ($0.16M proceeds)

8-K filing: BioSig Technologies, Inc. sold 1,665,384 shares of common stock to an accredited investor at $0.7806 per share, along with a warrant to purchase up to 832,692 shares at an exercise price of $0.7181 per share, for total consideration of $1,299,998.75. ($1.3M proceeds)

8-K filing: BioSig Technologies, Inc. sold 2,178,316 shares of common stock and warrants to purchase up to 1,089,158 shares of common stock to certain institutional and accredited investors for $1,254,884.28. ($1.25M proceeds)

8-K filing: BioSig Technologies, Inc. sold 2,161,598 shares of common stock at $0.508 per share and warrants to purchase 1,080,799 shares at an exercise price of $0.4455 per share for $1,098,091.79 in a private placement. Additionally, they sold 3,541,469 shares of common stock at $0.41 per share for $1,452,000 in a previous private placement and issued warrants to Laidlaw & Company (UK) Ltd. to purchase 60,976 and 49,213 shares of common stock. ($2.55M proceeds)

8-K filing: BioSig Technologies, Inc. sold 3,541,469 shares of common stock at $0.41 per share, raising $1,452,000, and issued 510,000 shares from warrant exercises for $127,500. ($1.58M proceeds)

10-Q filing | 48.0M shares outstanding

10-Q filing | 44.8M shares outstanding

8-K filing: BioSig Technologies, Inc. closed an underwritten public offering of 4,341,667 shares of common stock on June 29, 2022, and issued warrants to the underwriter to purchase 217,083 shares of common stock.

8-K filing: BioSig Technologies, Inc. completed a best efforts public offering of 4,341,667 shares of common stock at a price of $0.75 per share, expecting net proceeds of $3,030,880.23 before offering expenses. ($3.26M proceeds)

10-Q filing | 39.6M shares outstanding

10-K filing | 38.4M shares outstanding

8-K filing: BioSig Technologies, Inc. entered into a Securities Purchase Agreement to issue and sell 2,613,130 shares of common stock at $1.15 per share and warrants to purchase up to 2,613,130 shares at an exercise price of $1.40 per share, for gross proceeds of approximately $3.0 million in a registered direct offering that closed on March 22, 2022. ($3.0M proceeds)

8-K filing: BioSig Technologies, Inc. appointed Mr. John Sieckhaus as the Chief Operating Officer of the Company, whose employment commenced on March 21, 2022, and granted him 50,000 fully vested shares of the Company's common stock and stock options to acquire up to 350,000 shares of the Company's common stock.

10-Q filing | 35.3M shares outstanding

10-Q filing | 34.9M shares outstanding

8-K filing: BioSig Technologies, Inc. closed an underwritten public offering of 2,500,000 shares of common stock on July 7, 2021, and issued warrants to purchase 125,000 shares to the underwriter.

8-K filing: BioSig Technologies, Inc. entered into an underwriting agreement with Laidlaw & Company (UK) Ltd. for a public offering of 2,500,000 shares of common stock at $4.00 per share, with the Underwriter purchasing the shares at $3.68 per share, and granting the underwriter an option to purchase up to 375,000 additional shares. ($9.2M proceeds)

10-Q filing | 32.2M shares outstanding

10-K filing | 31.8M shares outstanding

S-3 filing: The company may offer and sell any combination of common stock and preferred stock up to an aggregate amount of $75,000,000.

10-Q filing | 30.2M shares outstanding

10-Q filing | 29.6M shares outstanding

8-K filing: BioSig Technologies, Inc. entered into a Securities Purchase Agreement to issue and sell 2,187,500 shares of common stock at $8.00 per share in a registered direct offering, for gross proceeds of approximately $17.5 million before fees and expenses. ($17.5M proceeds)

8-K filing: ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies, Inc., sold 1,068,550 shares of common stock at $10.00 per share for $10,685,500 in a private placement that closed on May 20, 2020. ($10.69M proceeds)

10-Q filing | 26.2M shares outstanding

10-K filing | 26.0M shares outstanding

8-K filing: BioSig Technologies, Inc. completed a public offering of 2,500,000 shares of common stock at $4.00 per share, with the underwriter purchasing the shares at $3.68 per share, resulting in net proceeds of $9,200,000 before offering expenses. ($9.2M proceeds)